immunogen europe limited
immunogen europe limited Company Information
Company Number
05592199
Website
-Registered Address
2nd floor, 168 shoreditch high street, london, E1 6RA
Industry
Non-trading company
Telephone
-
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
immunogen u.s. holding inc. 100%
immunogen europe limited Estimated Valuation
Pomanda estimates the enterprise value of IMMUNOGEN EUROPE LIMITED at £0 based on a Turnover of £0 and 0.46x industry multiple (adjusted for size and gross margin).
immunogen europe limited Estimated Valuation
Pomanda estimates the enterprise value of IMMUNOGEN EUROPE LIMITED at £0 based on an EBITDA of £0 and a 3.95x industry multiple (adjusted for size and gross margin).
immunogen europe limited Estimated Valuation
Pomanda estimates the enterprise value of IMMUNOGEN EUROPE LIMITED at £2 based on Net Assets of £1 and 2.23x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Immunogen Europe Limited AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Immunogen Europe Limited Overview
Immunogen Europe Limited is a live company located in london, E1 6RA with a Companies House number of 05592199. It operates in the non-trading company sector, SIC Code 74990. Founded in October 2005, it's largest shareholder is immunogen u.s. holding inc. with a 100% stake. Immunogen Europe Limited is a established, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Immunogen Europe Limited Health Check
There is insufficient data available to calculate a health check for Immunogen Europe Limited. Company Health Check FAQs
0 Strong
0 Regular
1 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Immunogen Europe Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Immunogen Europe Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- Immunogen Europe Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- Immunogen Europe Limited
- - Industry AVG
Employees
There is insufficient data available for this Key Performance Indicator!
- - Immunogen Europe Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Immunogen Europe Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Immunogen Europe Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Immunogen Europe Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Immunogen Europe Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Immunogen Europe Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Immunogen Europe Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 100%, this is a higher level of debt than the average (48.5%)
- - Immunogen Europe Limited
- - Industry AVG
immunogen europe limited Credit Report and Business Information
Immunogen Europe Limited Competitor Analysis
Perform a competitor analysis for immunogen europe limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
immunogen europe limited Ownership
IMMUNOGEN EUROPE LIMITED group structure
Immunogen Europe Limited has no subsidiary companies.
Ultimate parent company
IMMUNOGEN INC
#0107747
1 parent
IMMUNOGEN EUROPE LIMITED
05592199
immunogen europe limited directors
Immunogen Europe Limited currently has 3 directors. The longest serving directors include Ms Renee Lentini (Dec 2022) and Mr Daniel Char (Dec 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Ms Renee Lentini | United Kingdom | 46 years | Dec 2022 | - | Director |
| Mr Daniel Char | United Kingdom | 63 years | Dec 2022 | - | Director |
| Mr Todd Manning | United Kingdom | 53 years | Feb 2024 | - | Director |
IMMUNOGEN EUROPE LIMITED financials
Immunogen Europe Limited's latest turnover from December 2022 is estimated at 0 and the company has net assets of £1. According to their latest financial statements, we estimate that Immunogen Europe Limited has no employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Oct 2021 | Oct 2020 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||||||||
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | ||||||||||||||
| Gross Profit | ||||||||||||||
| Admin Expenses | ||||||||||||||
| Operating Profit | ||||||||||||||
| Interest Payable | ||||||||||||||
| Interest Receivable | ||||||||||||||
| Pre-Tax Profit | ||||||||||||||
| Tax | ||||||||||||||
| Profit After Tax | ||||||||||||||
| Dividends Paid | ||||||||||||||
| Retained Profit | ||||||||||||||
| Employee Costs | ||||||||||||||
| Number Of Employees | ||||||||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Oct 2021 | Oct 2020 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 16,144 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 16,144 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total assets | 16,145 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 16,144 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 16,144 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 16,144 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| net assets | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total shareholders funds | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2022 | Oct 2021 | Oct 2020 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | ||||||||||||||
| Depreciation | 0 | 0 | 0 | |||||||||||
| Amortisation | 0 | 0 | 0 | |||||||||||
| Tax | ||||||||||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | ||||||||||||||
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 16,144 | -1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 16,144 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | ||||||||||||||
| cash flow from financing | ||||||||||||||
| cash and cash equivalents | ||||||||||||||
| cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
P&L
December 2022turnover
0
0%
operating profit
0
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
1
0%
total assets
16.1k
+16144%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
immunogen europe limited company details
company number
05592199
Type
Private limited with Share Capital
industry
74990 - Non-trading company
incorporation date
October 2005
age
19
accounts
Small Company
ultimate parent company
previous names
N/A
incorporated
UK
address
2nd floor, 168 shoreditch high street, london, E1 6RA
last accounts submitted
December 2022
immunogen europe limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 3 charges/mortgages relating to immunogen europe limited. Currently there are 0 open charges and 3 have been satisfied in the past.
immunogen europe limited Companies House Filings - See Documents
| date | description | view/download |
|---|
